Skip to main content
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1990 Oct;81(10):971–974. doi: 10.1111/j.1349-7006.1990.tb03333.x

The Significance of Erythrocyte Sedimentation Rate as a Prognostic Factor for Patients with Prostate Cancer: Gunma Urological Oncology Study Group Investigation

Kyoichi Imai 1, Takanori Suzuki 1, Mikio Kobayashi 1, Hidetoshi Yamanaka 1, Yukio Tomaru 2, Jin Sato 3
PMCID: PMC5917967  PMID: 2121683

Abstract

The Gunma Urological Oncology Study Group has performed a multivariate statistical analysis of prognostic factors based on 353 patients with prostate cancer diagnosed between 1974 and 1984. This paper discusses the prognostic significance of erythrocyte sedimentation rate (ESR) in these patients with prostate cancer. Based on three ranges (<20, >20‐ <50, >50 mm/h) of ESR, a significant difference of survival rates among the patients was found by means of univariate analysis. ESR apparently includes components which represent anemia or infection. Hemoglobin, frequently used as a prognostic factor, was compared with ESR by means of multivariate analysis, and ESR was found to be a more useful prognostic factor than hemoglobin. Moreover ESR showed the highest partial coefficient value among the items studied (clinical stage, pathological differentiation, age, acid phosphatase, gait disturbance). It seems that ESR includes not only anemia and infection components but also provides a clue to the degree of bone metastasis or the degree of prostate cancer progression.

Keywords: Prostate cancer, Erythrocyte sedimentation rate, Prognostic factor

Full Text

The Full Text of this article is available as a PDF (403.4 KB).

References

  • 1.Adami, H., Norlen, B. J., Malker, B. and Merik, O.Long‐term survival in prostate carcinoma, with special reference to age as a prognostic factor. Scand. J. Urol. Nephrol., 20, 107–112 (1986). [DOI] [PubMed] [Google Scholar]
  • 2.Byar, D. P., Huse, R., Bailar, J. C., III and the Veterans Administration Cooperative Urological Research Group . An exponential model relating censored survival data and concomitant information for prostatic cancer patients. J. Natl. Cancer Inst., 52, 321–327 (1974). [DOI] [PubMed] [Google Scholar]
  • 3.Emrich, L. J., Priore, R. L., Murphy, J. P., Brady, M. F. and the investigation of the National Prostatic Cancer Project Prognostic factors in patients with advanced stage prostate cancer. Cancer Res., 45, 5173–5179 (1985). [PubMed] [Google Scholar]
  • 4.Tomaru, T., Koya, K., Kumasaka, H., Satoh, J., Imai, K. and Yamanaka, H.Multivariate analysis study of prognostic factor for prostate cancer. J. Jpn. Soc. Cancer Ther., 22, 1970 (1987) (in Japanese). [Google Scholar]
  • 5.Catalona, W. J. and Scott, W. S.Carcinoma of the prostate In“Campbell's Urology, 4th Edition,” ed. Harrison J. H., Gittes R. F., Perlmutter A. D., Stamey T. A. and Walsh P. C., p. 1092 (1979). W. B. Saunders Co., Philadelphia. [Google Scholar]
  • 6.Pilepich, M. V., Krall, J. M., Sause, W. T., Johnson, R. J., Russ, H. H., Hanks, G. E., Perez, C. A., Zinninger, M. Z. and Martz, K. L.Prognostic factors in carcinoma of prostate. Analysis of RTOG study 75‐06. Int. J. Radiat. Oncol. Biol. Phys., 13, 339–349 (1987). [DOI] [PubMed] [Google Scholar]
  • 7.Byar, D. P. and Corle, D. K.Analysis of prognostic factors for prostate cancer in the VACURG studies In“Controlled Clinical Trials in Urological Oncology,” ed. Denis L., Murphy G. P., Prout G. R. and Schreder F., pp. 147–186 (1984). Raven Press, New York. [Google Scholar]
  • 8.Sylvester, R. J., Suciu, S. and Yamanaka, H.Prognostic factors for randomization and stratification and endpoints for the evaluation trials In“EORTCG Genitourinary Group Monograph 5: Progress and Controversies in Oncological Urology II,” pp. 257–287 (1988). Alan R. Liss, Inc., New York. [PubMed] [Google Scholar]
  • 9.Wilson, D. W., Hraper, M. E., Jensen, H. M., Ikeda, R. M., Richards, G., Peeling, W. B., Pierrepoint, C. G. and Griffiths, K.A prognostic index for clinical management of patients with advanced prostate cancer, A British Prostate Study Group Investigation. Prostate, 7, 131–141 (1985). [DOI] [PubMed] [Google Scholar]
  • 10.Dayal, H. H., Polissar, L. and Dahlberg, S.Race, socioeconomic status and other prognostic factors for survival from prostate cancer. J. Natl. Cancer Inst., 74, 1001–1006 (1985). [PubMed] [Google Scholar]
  • 11.Catalona, W. J. and Scott, W. W.Carcinoma of the prostate In“Campbell's Urology, 5th Edition,” ed. Walsh P. C., Gittes R. F., Perlmutter A. D. and Stamey T. A., pp. 1463–1534 (1986). W. B. Saunders Co., Philadelphia. [Google Scholar]
  • 12.Mutoh, Y.Erythrocyte sedimentation rate. Medicina, 26, 1742–1743 (1989) (in Japanese). [Google Scholar]
  • 13.Soloway, M. S., Hardeman, S. W., Hickey, D., Raymond, J., Todd, B., Soloway, S. and Moinuddin, M.Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61, 195–202 (1988). [DOI] [PubMed] [Google Scholar]
  • 14.Hurukawa, T. and Tanaka, H.“Multiple Regression Analysis. Quantification I∼II. Program Package for Multivariate Analysis,” 1st Ed., pp. 17–39; pp. 128–150 (1983). Igakushoin, Tokyo (in Japanese). [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES